DAVID N. ORTH, MD., F.A.C.P.
A recent paper in the British Medical Journal (1) has recommended the use of metyrapone (Metopirone®; 2-methyl-1,2-bis(3-pyridyl)-1-propanone) for long-term treatment of patients with pituitary ACTH-dependent Cushing's syndrome (bilateral adrenal hyperplasia). Metyrapone inhibits the final step in adrenal steroid biosynthesis—the conversion of biologically inactive 11-deoxycortisol to cortisol (2). Metyrapone and aminoglutethimide (Elipten®; α-ethyl-α-p-aminophenylglutarimide), an agent that blocks the first step in steroid biosynthesis (3), have long been used to reduce hypercortisolism associated with adrenocortical tumors or ectopic ACTH syndrome (4-6); the only novelty in the British report lies in the use of such agents in Cushing's disease. What is the pathophysiology
Learn more about subscription options.
Register Now for a free account.
ORTH DN. Metyrapone Is Useful Only as Adjunctive Therapy in Cushing's Disease. Ann Intern Med. 1978;89:128–130. doi: 10.7326/0003-4819-89-1-128
Download citation file:
Published: Ann Intern Med. 1978;89(1):128-130.
Adrenal Disorders, Endocrine and Metabolism.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only